What is HC Wainwright’s Estimate for BioLineRx Q3 Earnings?

BioLineRx Ltd. (NASDAQ:BLRX) – Analysts at HC Wainwright issued their Q3 2026 earnings estimates for shares of BioLineRx in a report issued on Monday, August 31st. HC Wainwright analyst J. Pantginis expects that the biotechnology company will earn ($0.77) per share for the quarter. HC Wainwright also issued estimates for BioLineRx’s Q4 2026 earnings at ($0.80) EPS, FY2026 earnings at ($3.14) EPS and FY2027 earnings at ($2.52) EPS.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of BioLineRx in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

BioLineRx Trading Down 1.4%

Shares of BioLineRx stock opened at $2.76 on Wednesday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.43 and a current ratio of 1.58. The company has a market capitalization of $12.06 million, a P/E ratio of -1.63 and a beta of 1.56. BioLineRx has a 1 year low of $2.15 and a 1 year high of $4.56. The company’s fifty day moving average is $2.90 and its two-hundred day moving average is $2.83.

BioLineRx (NASDAQ:BLRX) last announced its quarterly earnings results on Monday, August 31st. The biotechnology company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.62). BioLineRx had a negative return on equity of 32.91% and a negative net margin of 502.08%.The company had revenue of $0.29 million for the quarter, compared to analyst estimates of $0.50 million.

BioLineRx Company Profile

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.